@jatwanikaran I'm still not seeing how this is measured, and whether you can measure the "harm" of distress. We intuitively know a distressed patient is not a good thing but if we can't easily measure it, we have more difficulty knowing what works and doesn't work to improve things.
We are thrilled to share a recent publication from @OncJournal Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study
π: https://t.co/S4RvXvzG10 #TOeJC
@OncJournal@realbowtiedoc@crisbergerot@montypal@jatwanikaran Exited to ehear the discussion on the recent paper in The Oncologist "Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study"!!!
OCE's @GautamMehtaMD and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxkiβthe first targeted treatment option for patients with HER2-mutated non-small cell lung cancer - via @OncJournal
https://t.co/lqWTdIbNwq
#OCEPublications#lcsm#NSCLC
@OUPMedicine @OncJournal Excited to meet people. But! Exhibit Hall still under construction. So no meeting today. Will also be there Sunday at 12:30 pm! Hope to see you there. Booth 10076
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials - via @OncJournal. https://t.co/7XgobG89t3
#OCEPublications
@OncJournal This Commentary sheds light on a lot of the concerns about Hospice that our patients have regarding βaccess to high quality hospice careβ¦.β
@MDRoeland @OncJournal@ASCO@MASCC Thank you for highlighting this paper in @OncJournal. This is an understudied source of misery for many patients with #cancer. We've published on this before. https://t.co/3cZ4Fs1T5S; https://t.co/ZuxtJJ5gaY